According to a report named “Dental Biomaterials Market by Type (Metallic (Titanium, Stainless Steel, Chromium Alloy, Amalgam, Gold), PFM, Ceramic, Bone Graft, Polymer Biomaterials), Application (Implantology, Prosthetic, Orthodontic), End User – Global Forecast to 2023” published by MarketsandMarkets the market for Dental Biomaterial will reach 9.6 billion US$ in the year 2023 from 6.7 billion US$ in 2018. The CAGR during this time will be 7.4 %. The increased income, population, dental tourism in developing countries and dental disorders are the major factors for the increase in the growth of the market.
The Dental Biomaterials is divided into many types of products such as ceramic, natural biomaterial, metal ceramic, ceramic and polymeric. Dental Biomaterials Market was dominated by metallic biomaterial in the year 2018. metallic biomaterials had the largest market share due to an increase in the extensive use of it in dentistry and the penetration of dental implants.
The Dental Biomaterials Market is divided into several types based on the use, these types include prosthodontics, orthodontics, implantology, and other applications. The year 2018 saw the increase in implantology and it had the largest market share. The factors responsible for the large share of implantology includes High price of the implants, the increased use of titanium requirement, increase in cosmetic dentistry, increase income in the developing countries and the increase in dental diseases.
The dental market is divided into five regions which include, Europe, Latin America, Asia Pacific, the Middle East & Africa, and North America. In the year 2018 Europe has the largest share of Dental Biomaterial Market. The major factors responsible for the increase in the Dental Biomaterials Market shares includes The increased government investments in oral care, The growth in dental hospitals and clinics The increased use of dental biomaterials in the dental products and the growth in general population.
The major vendors of Dental Biomaterials Market include Institut Straumann AG (Switzerland), BEGO Medical GmbH (Germany), Cam Bioceramics B.V (Netherland), Carpenter Technology Corporation (US), Danaher Corporation (US), Datum Dental Ltd (Israel), Dentsply Sirona, Inc. (US), 3M Company (US), GC Corporation (Japan), Keystone Dental, Inc. (US), Geistlich Pharma AG (Switzerland), Ivoclar Vivadent AG (Principality of Liechtenstein), Kuraray Co., Ltd (Japan), Medtronic Plc. (Ireland), Henry Schein, Inc. (US), Mitsui Chemicals Inc. (Japan), Royal DSM (Netherlands), Victrex Plc (UK) and Zimmer Biomet Holdings, Inc. (US).